Literature DB >> 31580415

Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes.

Yaping Chu1, Scott Muller1, Adriana Tavares2, Olivier Barret2, David Alagille2, John Seibyl2, Gilles Tamagnan2, Ken Marek2, Kelvin C Luk3,4, John Q Trojanowski3, Virginia M Y Lee3, Jeffrey H Kordower1.   

Abstract

Several studies have demonstrated that intrastriatal injections of fibrillar α-synuclein in rodent brain induced a Parkinson's disease-like propagation of Lewy body pathology with significant nigrostriatal neurodegeneration. This study evaluated the pathological features when exogenous α-synuclein preformed fibrils were injected into the putamen of non-human primates. Eight cynomolgus monkeys received unilateral intraputamen injections of α-synuclein preformed fibrils and four monkeys received sham surgery. Monkeys were assessed with 123I-PE2I single-photon emission computerized tomography scans targeting the dopamine transprter at baseline, 3, 6, 9, 12, and 15 months. Imaging revealed a robust increase in dopamine transporter binding, an effect confirmed by port-mortem immunohistochemical analyses, suggesting that upregulation of dopamine transporter occurs as part of an early pathological process. Histochemistry and immunohistochemistry revealed that α-synuclein preformed fibrils injections into the putamen induced intraneuronal inclusions positive for phosphorylated α-synuclein in ipsilateral substantia nigra and adjacent to the injection site. α-Synuclein inclusions were thioflavin-S-positive suggesting that the inclusions induced by α-synuclein preformed fibrils exhibited pathological properties similar to amyloid-like Lewy body pathology in Parkinson's disease brains. The α-synuclein preformed fibrils resulted in Lewy pathology in the ipsilateral substantia nigra with significant reduction (-29.30%) of dopaminergic neurons as compared with controls. Nigral neurons with α-synuclein inclusions exhibited a phenotypic downregulation of the dopamine markers tyrosine hydroxylase and Nurr1. Taken together, our findings demonstrate that α-synuclein preformed fibrils induce a synucleinopathy in non-human primates with authentic Lewy pathology and nigrostriatal changes indicative of early Parkinson's disease.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Lewy bodies; neurodegeneration; nigrostriatal system; propagation; α-synuclein

Mesh:

Substances:

Year:  2019        PMID: 31580415      PMCID: PMC7962904          DOI: 10.1093/brain/awz296

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  68 in total

1.  Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.

Authors:  R P Irwin; J G Nutt; W R Woodward; S T Gancher
Journal:  Clin Neuropharmacol       Date:  1992-10       Impact factor: 1.592

2.  A new strategy for analysis of phenotype marker antigens in hollow neurospheres.

Authors:  Michael L Moeller; S Dan Dimitrijevich
Journal:  J Neurosci Methods       Date:  2004-10-15       Impact factor: 2.390

3.  Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates.

Authors:  Laura A Volpicelli-Daley; Kelvin C Luk; Virginia M-Y Lee
Journal:  Nat Protoc       Date:  2014-08-14       Impact factor: 13.491

Review 4.  Nurr1-Based Therapies for Parkinson's Disease.

Authors:  Jie Dong; Song Li; Jing-Lin Mo; Huai-Bin Cai; Wei-Dong Le
Journal:  CNS Neurosci Ther       Date:  2016-03-25       Impact factor: 5.243

5.  Orphan nuclear receptor Nurr1 is essential for Ret expression in midbrain dopamine neurons and in the brain stem.

Authors:  A Wallén A; D S Castro; R H Zetterström; M Karlén; L Olson; J Ericson; T Perlmann
Journal:  Mol Cell Neurosci       Date:  2001-12       Impact factor: 4.314

6.  Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?

Authors:  Yaping Chu; Jeffrey H Kordower
Journal:  Neurobiol Dis       Date:  2006-10-18       Impact factor: 5.996

7.  alpha-Synuclein pathology in the neostriatum in Parkinson's disease.

Authors:  Fumiaki Mori; Kunikazu Tanji; Haixin Zhang; Akiyoshi Kakita; Hitoshi Takahashi; Koichi Wakabayashi
Journal:  Acta Neuropathol       Date:  2007-11-14       Impact factor: 17.088

8.  Dopamine neuron agenesis in Nurr1-deficient mice.

Authors:  R H Zetterström; L Solomin; L Jansson; B J Hoffer; L Olson; T Perlmann
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

9.  Differential effects of advancing age on neurotransmitter cell loss in the substantia nigra and striatum of C57BL/6N mice.

Authors:  T H McNeill; L L Koek
Journal:  Brain Res       Date:  1990-06-25       Impact factor: 3.252

10.  Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation.

Authors:  Giulia Panattoni; Lucia Rota; Emanuela Colla
Journal:  J Vis Exp       Date:  2018-06-26       Impact factor: 1.355

View more
  32 in total

Review 1.  Reverse engineering Lewy bodies: how far have we come and how far can we go?

Authors:  Mohamed Bilal Fares; Somanath Jagannath; Hilal A Lashuel
Journal:  Nat Rev Neurosci       Date:  2021-01-11       Impact factor: 34.870

Review 2.  Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases.

Authors:  Gouri Chopra; Shabnam Shabir; Sumaira Yousuf; Simran Kauts; Shahnawaz A Bhat; Ashiq H Mir; Mahendra P Singh
Journal:  Mol Neurobiol       Date:  2022-10-07       Impact factor: 5.682

Review 3.  The role of NURR1 in metabolic abnormalities of Parkinson's disease.

Authors:  Murad Al-Nusaif; Yuting Yang; Song Li; Cheng Cheng; Weidong Le
Journal:  Mol Neurodegener       Date:  2022-06-27       Impact factor: 18.879

Review 4.  Exosomes in Parkinson disease.

Authors:  Jennifer R Pinnell; Mei Cui; Kim Tieu
Journal:  J Neurochem       Date:  2021-01-22       Impact factor: 5.372

Review 5.  Evidence of distinct α-synuclein strains underlying disease heterogeneity.

Authors:  Sara A M Holec; Amanda L Woerman
Journal:  Acta Neuropathol       Date:  2020-05-21       Impact factor: 17.088

Review 6.  Brain regions susceptible to alpha-synuclein spreading.

Authors:  Yu-Jie Guo; Huan Xiong; Kang Chen; Jin-Jun Zou; Peng Lei
Journal:  Mol Psychiatry       Date:  2021-09-24       Impact factor: 15.992

7.  Modulation effect of substantia nigra iron deposition and functional connectivity on putamen glucose metabolism in Parkinson's disease.

Authors:  Zhenxiang Zang; Tianbin Song; Jiping Li; Shaozhen Yan; Binbin Nie; Shanshan Mei; Jie Ma; Yu Yang; Baoci Shan; Yuqing Zhang; Jie Lu
Journal:  Hum Brain Mapp       Date:  2022-04-26       Impact factor: 5.399

Review 8.  A New Rise of Non-Human Primate Models of Synucleinopathies.

Authors:  Margaux Teil; Marie-Laure Arotcarena; Benjamin Dehay
Journal:  Biomedicines       Date:  2021-03-09

Review 9.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26

10.  Preformed fibrils generated from mouse alpha-synuclein produce more inclusion pathology in rats than fibrils generated from rat alpha-synuclein.

Authors:  Jacob W Howe; Caryl E Sortwell; Megan F Duffy; Christopher J Kemp; Christopher P Russell; Michael Kubik; Pooja Patel; Kelvin C Luk; Omar M A El-Agnaf; Joseph R Patterson
Journal:  Parkinsonism Relat Disord       Date:  2021-06-19       Impact factor: 4.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.